BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R;  BIOFLOW V Investigators. Ultrathin, bioresorbable polymer sirolimus-eluting stents vs thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017;390:1843-1852. [PMID: 28851504 DOI: 10.1016/s0140-6736(17)32249-3] [Cited by in Crossref: 154] [Cited by in F6Publishing: 21] [Article Influence: 38.5] [Reference Citation Analysis]
Number Citing Articles
1 Buiten RA, Ploumen EH, Zocca P, Doggen CJM, van der Heijden LC, Kok MM, Danse PW, Schotborgh CE, Scholte M, de Man FHAF, Linssen GCM, von Birgelen C. Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial. JAMA Cardiol 2019;4:659-69. [PMID: 31111862 DOI: 10.1001/jamacardio.2019.1776] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 29.0] [Reference Citation Analysis]
2 Kobo O, Saada M, Meisel SR, Hellou E, Frimerman A, Fanne RA, Mohsen J, Danon A, Roguin A. Modern Stents: Where Are We Going? Rambam Maimonides Med J 2020;11. [PMID: 32374258 DOI: 10.5041/RMMJ.10403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yun KH, Lee SY, Cho BR, Jang WJ, Song YB, Oh JH, Chun WJ, Park YH, Im ES, Jeong JO, Oh SK, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Lee WS, Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC, Hahn JY; SMART‐CHOICE Investigators [Link]. Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial. J Am Heart Assoc 2021;10:e018366. [PMID: 33345567 DOI: 10.1161/JAHA.120.018366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her AY, Cho S, Jeon DW, Yoo SY, Cho DK, Hong BK, Kwon H, Ahn CM, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y; TICO Investigators. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA 2020;323:2407-16. [PMID: 32543684 DOI: 10.1001/jama.2020.7580] [Cited by in Crossref: 98] [Cited by in F6Publishing: 70] [Article Influence: 98.0] [Reference Citation Analysis]
5 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2019;40:2632-53. [PMID: 31116395 DOI: 10.1093/eurheartj/ehz372] [Cited by in Crossref: 128] [Cited by in F6Publishing: 72] [Article Influence: 128.0] [Reference Citation Analysis]
6 Kharlamov AN. Undiscovered pathology of transient scaffolding t1remains a driver of failures in clinical trials. World J Cardiol 2018;10:165-86. [PMID: 30386494 DOI: 10.4330/wjc.v10.i10.165] [Reference Citation Analysis]
7 Waliszewski M, Rosenberg M, Rittger H, Breul V, Krackhardt F. Endpoint selection for noninferiority percutaneous coronary intervention trials: a methodological description. Ther Adv Cardiovasc Dis 2020;14:1753944720911329. [PMID: 32168991 DOI: 10.1177/1753944720911329] [Reference Citation Analysis]
8 Ozaki Y, Katagiri Y, Onuma Y, Amano T, Muramatsu T, Kozuma K, Otsuji S, Ueno T, Shiode N, Kawai K, Tanaka N, Ueda K, Akasaka T, Hanaoka KI, Uemura S, Oda H, Katahira Y, Kadota K, Kyo E, Sato K, Sato T, Shite J, Nakao K, Nishino M, Hikichi Y, Honye J, Matsubara T, Mizuno S, Muramatsu T, Inohara T, Kohsaka S, Michishita I, Yokoi H, Serruys PW, Ikari Y, Nakamura M; Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Cardiovascular Interventional Therapeutics (CVIT). CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018. Cardiovasc Interv Ther 2018;33:178-203. [PMID: 29594964 DOI: 10.1007/s12928-018-0516-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 24] [Article Influence: 16.7] [Reference Citation Analysis]
9 Madhavan MV, Howard JP, Naqvi A, Ben-Yehuda O, Redfors B, Prasad M, Shahim B, Leon MB, Bangalore S, Stone GW, Ahmad Y. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J 2021;42:2643-54. [PMID: 34002202 DOI: 10.1093/eurheartj/ehab280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Wu JJ, Way JAH, Roy P, Yong A, Lowe H, Kritharides L, Brieger D. Biodegradable polymer versus second-generation durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis. Health Sci Rep 2018;1:e93. [PMID: 30623046 DOI: 10.1002/hsr2.93] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Kim SH, Kang SH, Lee JM, Chung WY, Park JJ, Yoon CH, Suh JW, Cho YS, Doh JH, Cho JM, Bae JW, Youn TJ, Chae IH. Three-year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent: A randomized controlled trial. Catheter Cardiovasc Interv 2020;96:1399-406. [PMID: 31859438 DOI: 10.1002/ccd.28654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
12 Zocca P, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, Hartmann M, Linssen GCM, Doggen CJM, von Birgelen C. High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial. Cardiovasc Drugs Ther 2018;32:567-76. [PMID: 30143879 DOI: 10.1007/s10557-018-6823-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Sinha SK, Aggarwal P, Pandey U, Razi M, Kumar A, Krishna V. Ultrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients. Anatol J Cardiol 2021;25:111-9. [PMID: 33583818 DOI: 10.14744/AnatolJCardiol.2020.40909] [Reference Citation Analysis]
14 Choudhury A, Garg S, Smith J, Sharp A, Nabais de Araujo S, Chauhan A, Patel N, Wrigley B, Chattopadhyay S, Zaman AG. Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months' results from the S-FLEX UK registry. BMJ Open 2019;9:e026578. [PMID: 31604782 DOI: 10.1136/bmjopen-2018-026578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Iannaccone M, Barbero U, De Benedictis M, Imori Y, Quadri G, Trabattoni D, Ryan N, Venuti G, Montabone A, Wojakowski W, Rognoni A, Helft G, Parma R, De Luca L, Autelli M, Boccuzzi G, Mattesini A, Templin C, Cerrato E, Wańha W, Smolka G, Huczek Z, Tomassini F, Cortese B, Capodanno D, Chieffo A, Nuñez-Gil I, Gili S, Bassignana A, di Mario C, Doronzo B, Omedè P, D'Amico M, Tedeschi D, Varbella F, Luscher T, Sheiban I, Escaned J, Rinaldi M, D'Ascenzo F. Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from the RAIN-CARDIOGROUP VII Study). BMC Cardiovasc Disord 2020;20:225. [PMID: 32414330 DOI: 10.1186/s12872-020-01420-5] [Reference Citation Analysis]
16 Zhu P, Zhou X, Zhang C, Li H, Zhang Z, Song Z. Safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer drug-eluting stents: a meta-analysis of randomized trials. BMC Cardiovasc Disord 2018;18:170. [PMID: 30111289 DOI: 10.1186/s12872-018-0902-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
17 Rigatelli G, Zuin M, Dash D. Thin and crush: The new mantra in left main stenting? World J Cardiol 2018;10:191-5. [PMID: 30510635 DOI: 10.4330/wjc.v10.i11.191] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cassese S, Lahmann AL, Joner M. Ultrathin strut biodegradable-polymer sirolimus-eluting stents: being wary or going with the flow? J Thorac Dis 2018;10:688-92. [PMID: 29607135 DOI: 10.21037/jtd.2018.01.118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
19 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation 2019;140:240-61. [PMID: 31116032 DOI: 10.1161/CIRCULATIONAHA.119.040167] [Cited by in Crossref: 162] [Cited by in F6Publishing: 29] [Article Influence: 81.0] [Reference Citation Analysis]
20 Lupi A, Schaffer A, Bongo AS. Should ultrathin strut drug eluting stents be considered the new benchmark for novel coronary stents approval? The complex interplay between stent strut thickness, polymeric carriers and antiproliferative drugs. J Thorac Dis 2018;10:678-81. [PMID: 29607133 DOI: 10.21037/jtd.2018.01.108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
21 Hansen KW, Jeger R, Sørensen R, Kaiser C, Pfisterer M, Biering-Sørensen T, Bjerking LH, Galatius S. Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials. BMC Cardiovasc Disord 2019;19:226. [PMID: 31619181 DOI: 10.1186/s12872-019-1199-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]